Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.
We assessed the long-term safety, effectiveness and quality of a fixed-dose combination of nevirapine, stavudine and lamivudine (triomune). HIV-1-infected adults initially enrolled in a one-year, open-label, single-arm, multicentre trial in Cameroon were followed for 2 years. Our results support the safety and effectiveness of the triomune combination for first-line treatment of HIV infection. Virological effectiveness appeared to wane somewhat during the second year of treatment, however, and plasma nevirapine concentrations were relatively high.
Laurent
Christian
C
IRD, UMR 145 (IRD/University of Montpellier 1), Montpellier, France. christian.Laurent@mpl.ird.fr
Kouanfack
Charles
C
Koulla-Shiro
Sinata
S
Njoume
Maguy
M
Nkene
Yvette Mawamba
YM
Ciaffi
Laura
L
Brulet
Charlotte
C
Peytavin
Gilles
G
Vergne
Laurence
L
Calmy
Alexandra
A
Mpoudi-Ngolé
Eitel
E
Delaporte
Eric
E
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D008134:Long-Term Care / Q000379:methods; D008297:Male; D019829:Nevirapine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D018119:Stavudine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D019829:Nevirapine; D018119:Stavudine